Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study (Q39217123)

10 September 2017

Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study (English)

1 reference

10 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Wendy Erber

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Tania Tabone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Hazem J Abuhusain

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Australian Genomics and Clinical Outcome of Glioma (AGOG) Network

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Kerrie L McDonald

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

2 April 2014

1 reference

Journal of Clinical Pathology

10 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

550-555

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695838%20AND%20SRC:MED&resulttype=core&format=json

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

The WHO classification of tumors of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Biomarkers classification and therapeutic decision-making for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Genetic markers in glioblastoma: prognostic significance and future therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

A multigene predictor of outcome in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

American Society of Clinical Oncology 2011 CNS tumors update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Emerging landscape of oncogenic signatures across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Biomarkers to predict response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Genetic alterations and signaling pathways in the evolution of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173

Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202173